Hostname: page-component-78c5997874-94fs2 Total loading time: 0 Render date: 2024-11-13T01:06:10.819Z Has data issue: false hasContentIssue false
  • English
  • Français

Long-term studies of antipsychotic drugs in schizophrenia — discussion

Published online by Cambridge University Press:  16 April 2020

HJ Möller
HJ Möller*
Affiliation:
Psychiatric Hospital, University of Munich, Nuβbaumstraβe 7, D-80336Munich, Germany
Get access

Abstract

An abstract is not available for this content so a preview has been provided. Please use the Get access link above for information on how to access this content.
Image of the first page of this content. For PDF version, please use the ‘Save PDF’ preceeding this image.'
Type
Research Article
Information
European Psychiatry , Volume 11 , Issue 3: Issues of Concern in the Standardization and Harmonization of Psychotropic Drug Trials in Europe , 1996 , pp. 135 - 136
Copyright
Copyright © Elsevier, Paris 1996

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Angst, JWoggon, BValidity of the AMP-system for its use in clinical psychopharmacology. In: Bobon, DBaumann, UAngst, JHelmchen, HHippius, H eds. AMDP-system in pharmacopsychiatry. London and New York: Karger, 1983; 174–184Google Scholar
Clare, AWCairns, VEDesign, development and use of a standardized interview to assess social maladjustment and dysfunction in community studies. Psychol Med 1978; 8: 589–604CrossRefGoogle ScholarPubMed
Collegium Internationale Psychiatriae Scalarum eds. Internationale Skalen für Psychiatrie. Basel: Beltz, 1981Google Scholar
Endicott, JSpitzer, RLFleiss, JLCohen, JThe Global Assessment Scale. A procedure for measuring overall severity of psychiatric disturbance. Arch Gen Psychiatry 1976; 33: 766–771CrossRefGoogle ScholarPubMed
Hecht, HFaltermaier, TWittchen, HUDie “Social Interview Schedule”. (deutsch-sprachige modifizierte Version) Weinheim: Roderer, 1987Google Scholar
Hiller, Wv Zerssen, DMombour, WWittchen, HUDie IMPS. Regensburg: Beltz, 1986Google Scholar
Jablensky, ASchwarz, RTomov, TWHO collaborative study on impairments and disabilities associated with schizophrenic disorders Acta Psychiatr Scand 1980 62 suppl 285 152–163CrossRefGoogle Scholar
Kay, SROpler, LAFiszbein, APositive and negative syndrome scale (PANSS) Rating Manual. Social and Behavioral Documents San Rafael/CA, 1987Google Scholar
Lingjaerde, OAhlfors, UGBech, PDencker, SJElgen, KThe UKU side effect rating scale. A new comprehensive rating scale for psychotropic drugs and a cross-sectional study of side effects in neuroleptic-treated patients Acta Psychiatr Scand 76suppl 3341987 1–100CrossRefGoogle Scholar
Lorr, MAssessing psychotic behavior by the IMPS Pichot, POlivier-Martin, RPsychological measurements in psychopharmacology. Modern problems in pharmacopsychiatry Basel: Karger, 1974; 7 50–63Google ScholarPubMed
Marder, SRvan Putten, TMintz, JLebell, MMcKenzie, JMay, PRALow- and conventional-dose maintenance therapy with fluphenazine decanoate. Arch Gen Psychiatry 1987; 44: 518–521CrossRefGoogle ScholarPubMed
Möller, HJHacker, HStudy concerning the sample dependency and temporal variance of the factor structure in the Inpatient Multidimensional Psychiatric Scale. Psychopathology 1988; 21: 281–290CrossRefGoogle ScholarPubMed
Overall, JEGorham, DRThe Brief Psychiatric Rating Scale. Psychol Rep 1962; 10: 799–812CrossRefGoogle Scholar
Simpson, GMAngus, JWSA rating scale for extrapyramidal side effects Acta Psychiatr Scand 1970 12 suppl 2 11–19CrossRefGoogle Scholar
Submit a response

Comments

No Comments have been published for this article.